Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 8, 2007, Pages 1256-1264

  Tacke, Frank ^a   Trautwein, Christian ^a   Yagmur, Eray ^a   Hellerbrand, Claus ^b   Wiest, Reiner ^b   Brenner, David A ^c   Schnabl, Bernd ^b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Department of Internal Medicine I University of Regensburg ^*  (United States)

Author keywords

CCR3; Chemokine; Eosinophil; Eotaxin; Hepatic stellate cell; Kupffer cell; Monocyte

Indexed keywords

EOTAXIN;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; PRIORITY JOURNAL; UPREGULATION;

EID: 34547679446     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04621.x     Document Type: Article

References (38)

1. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005 115 : 209 18.
2. Friedman SL. Mac the knife? Macrophages: the double-edged sword of hepatic fibrosis. J. Clin. Invest. 2005 115 : 29 32.
3. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005 128 : 138 46.
4. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 2005 115 : 56 65.
5. Streetz KL, Tacke F, Leifeld L et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003 38 : 218 29.
6. Tilg H, Wilmer A, Vogel W et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992 103 : 264 74.
7. Luedde T, Liedtke C, Manns MP, Trautwein C. Losing balance: cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure. Eur. Cytokine Netw. 2002 13 : 377 83.
8. Qu C, Edwards EW, Tacke F et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J. Exp. Med. 2004 200 : 1231 41.
9. Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J. Immunol. 2005 174 : 1549 56.
10. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006 211 : 609 18.
11. Marsillach J, Bertran N, Camps J et al. The role of circulating monocyte chemoattractant protein-1 as a marker of hepatic inflammation in patients with chronic liver disease. Clin. Biochem. 2005 38 : 1138 40.
12. Jaruga B, Hong F, Sun R, Radaeva S, Gao B. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J. Immunol. 2003 171 : 3233 44.
13. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003 37 : 653 64.
14. Pham BN, Bemuau J, Durand F et al. Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. J. Hepatol. 2001 34 : 537 47.
15. Tacke F, Brabant G, Kruck E et al. Ghrelin in chronic liver disease. J. Hepatol. 2003 38 : 447 54.
16. Tacke F, Schoffski P, Trautwein C, Manns MP, Ganser A, von Depka M. Tissue factor and thrombomodulin levels are correlated with stage of cirrhosis in patients with liver disease. Blood Coagul. Fibrinolysis 2001 12 : 539 45.
17. Tacke F, Luedde T, Manns MP, Trautwein C. Regulation of plasma erythropoietin in chronic liver disease. World J. Gastroenterol. 2004 10 : 2922 3.
18. Tacke F, Wustefeld T, Horn R et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005 42 : 666 73.
19. Tacke F, Schoffski P, Trautwein C et al. Plasma P-selectin levels are elevated in patients with chronic liver disease. Blood Coagul. Fibrinolysis 2003 14 : 319 25.
20. Korner T, Kropf J, Kosche B, Kristahl H, Jaspersen D, Gressner AM. Improvement of prognostic power of the Child-Pugh classification of liver cirrhosis by hyaluronan. J. Hepatol. 2003 39 : 947 53.
21. Tacke F, Fiedler K, von Depka M et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int. 2006 26 : 173 82.
22. Said A, Williams J, Holden J et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J. Hepatol. 2004 40 : 897 903.
23. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004 59 : 793 805.
24. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J. Hepatol. 2005 42 (Suppl. S100 7.
25. Sato E, Koyama S, Robbins RA. Bleomycin stimulates lung fibroblast and epithelial cell lines to release eosinophil chemotactic activity. Eur. Respir. J. 2000 16 : 951 8.
26. Haley KJ, Lilly CM, Yang JH et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000 102 : 2185 9.
27. Hogan SP, Rothenberg ME. Review article: the eosinophil as a therapeutic target in gastrointestinal disease. Aliment. Pharmacol. Ther. 2004 20 : 1231 40.
28. Bisset LR, Schmid-Grendelmeier P. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr. Opin. Pulm. Med. 2005 11 : 35 42.
29. Daldegan MB, Teixeira MM, Talvani A. Concentration of CCL11, CXCL8 and TNF-alpha in sputum and plasma of patients undergoing asthma or chronic obstructive pulmonary disease exacerbation. Braz. J. Med. Biol. Res. 2005 38 : 1359 65.
30. Emanuele E, Falcone C, D'Angelo A et al. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis 2006 186 : 140 5.
31. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003 26 : 2421 5.
32. Papayianni A, Alexopoulos E, Giamalis P et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol. Dial. Transplant. 2002 17 : 435 41.
33. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am. J. Gastroenterol. 2005 100 : 1981 3.
34. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev. Mol. Diagn. 2005 5 : 15 21.
35. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 50.
36. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004 10 : 429 34.
37. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int. 2004 24 : 437 45.
38. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C et al. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand. J. Gastroenterol. 2005 40 : 217 24.